CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 33 enrolled
Drug / intervention
Ixazomib Citrate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02339922
NCT02339922Phase 2Active
CompareCT.gov

A Window Study of Ixazomib in Untreated Indolent B-NHL

University of Washington·interventional·Posted Jan 16, 2015·Updated Mar 5, 2026

In Brief

A Phase 2 clinical trial evaluating Ixazomib Citrate, Laboratory Biomarker Analysis, and 1 other intervention for Chronic Lymphocytic Leukemia and 8 related conditions. Active but no longer recruiting, targeting 33 participants across 1 site.

Detailed Summary

This phase II trial studies how well ixazomib citrate and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that grows slowly (indolent). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving ixazomib citrate together with rituximab may work better in treating indolent B-cell non-Hodgkin lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2Active
20152016201720182019202020212022202320242025202620272028202920302031
First PostedJan 16, 2015
Enrollment StartMay 19, 2016
Primary CompletionDec 30, 2024
Study CompletionJan 6, 2031
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 11.5 years ago

Interventions

Ixazomib Citratedrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Rituximabbiological

Given IV